

Supplementary information

Accelerating therapeutic discoveries for heart failure: a new public–private partnership

In the format provided by the authors



Supplementary Fig. 1| **Accelerating Medicines Partnership in Heart Failure (AMP HF) project: design overview.** The AMP HF project utilizes the NHLBI HeartShare Study, which is divided into two components. The first component (years 1–2 of the project) will aggregate existing results from NIH and industry-sponsored trials and cohorts into the largest database available to investigate HFpEF subtypes and associated biomarkers and links to clinical outcomes. The second component (years 1–5 of the project) is a three-tiered prospective cohort study of patients with HFpEF. After successful completion of the 5-year HeartShare Study, it is expected that the AMP HF project will facilitate creation of a master protocol to test precision therapies in HFpEF. AMP, Accelerating Medicines Partnership; HF, heart failure; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; HFpEF, heart failure with preserved ejection fraction; ML, machine learning; Rx, treatment.